Examine the difference between a body-composition signal and functional improvement.
The selected ibutamoren study reported more fat-free mass without better strength or physical function. The other studies use different populations and regimens.
20 weeks; weekly enanthate with a GnRH agonist. These are experimental regimens.
Demonstrated findings
Across graded testosterone exposures, fat-free mass, muscle size and strength increased with dose. Mood and sexual function did not significantly change at any dose.
Selected groups from this experiment
Studied dose
Mean trough total T
Fat-free mass change
125 mg/week
542 ng/dL
+3.4 kg
300 mg/week
1,345 ng/dL
+5.2 kg
600 mg/week
2,370 ng/dL
+7.9 kg
Group averages at the studied regimens, not a dosing recommendation or prediction of personal gains.
Limitations & adverse findings
Hemoglobin increased and HDL cholesterol decreased with higher concentrations. Fat-free mass includes more than muscle.
What might this mean? · interpretation
Different outcomes can respond differently to increasing hormone exposure.
What might this mean, and what would change the interpretation?
61 healthy men aged 18–35; endogenous production was suppressed. Short-term group averages cannot predict an individual response.
What would clarify this: Longer trials measuring function and adverse outcomes across comparable exposures.
Findings reviewed · abstract
Checked Sep 15, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.
48 weeks; IV bimagrumab every 4 weeks, with diet and exercise counseling in both groups.
Demonstrated findings
At 48 weeks, fat mass changed by −20.5% with bimagrumab versus −0.5% with placebo; lean mass changed by +3.6% versus −0.8%.
Limitations & adverse findings
The report analyzed treatment completers, which can affect interpretation. The abstract provides limited adverse-event detail.
What might this mean? · interpretation
The result supports studying activin-receptor blockade for body composition.
What might this mean, and what would change the interpretation?
75 adults with type 2 diabetes and overweight or obesity were randomized; 58 completed. This was not a GLP combination trial and does not establish preserved strength.
What would clarify this: Controlled combination trials measuring both muscle composition and function.
Findings reviewed · abstract
Checked Sep 15, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.
When do changes in measured lean mass translate into better strength, mobility or exercise capacity?
DXA or other body-composition method
Regional muscle size
Strength and physical function
Fluid changes and follow-up duration
For emerging mechanisms, replication and the absence of the predicted effect both matter. Human implications remain hypotheses until the relevant outcomes are tested.
Community experiences & questions
A sourced community summary has not been prepared for this question yet. The compound pages link to public discussions for further exploration.
Self-selected accounts can reveal questions and experiences; they do not establish a response rate or verified product identity.